Sagent Pharmaceuticals Reports Third Quarter 2013 Financial Results
November 05, 2013 07:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced financial results for the quarter ended September 30, 2013.
Third Quarter 2013...
Sagent Pharmaceuticals Announces the Launch of Carboplatin Injection
November 04, 2013 08:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Carboplatin Injection, an antineoplastic agent, in four preservative-free...
Sagent Pharmaceuticals is Named Winner of 12th Annual Chicago Innovation Awards
October 31, 2013 16:01 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) has been named one of the winners of the 12th annual Chicago Innovation Awards.
The winners were...
Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2013 Financial Results
October 22, 2013 16:01 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Announces the Launch of Zoledronic Acid Injection 5 mg in a Premix Bag
October 11, 2013 16:18 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Zoledronic Acid Injection 5 mg, the generic form of the bisphosphonate...
Sagent Pharmaceuticals Announces Upsizing and Pricing of Offering of 4,600,000 Shares of Common Stock
September 10, 2013 21:01 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today...
Sagent Pharmaceuticals Announces Offering of 4,441,627 Shares of Common Stock
September 09, 2013 06:15 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Reports Second Quarter 2013 Financial Results
August 06, 2013 07:00 ET
|
Sagent Pharmaceuticals, Inc.
New Product Launches Drive Revenue and Record Earnings
Company Increases Earnings Outlook for 2013
SCHAUMBURG, Ill., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT),...
Sagent Pharmaceuticals Announces the Reintroduction of Amiodarone HCl Injection
August 05, 2013 13:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the reintroduction of Amiodarone HCl Injection, an antiarrhythmic agent, now in an...
Sagent Pharmaceuticals Announces the Approval of Zoledronic Acid Injection 4 mg per 100 mL in a Premix Bag
August 05, 2013 10:54 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the approval of Zoledronic Acid Injection 4 mg per 100 mL, the generic form of the...